{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:07:25Z","timestamp":1753272445577},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ygyno.2004.05.021","type":"journal-article","created":{"date-parts":[[2004,7,7]],"date-time":"2004-07-07T21:23:59Z","timestamp":1089235439000},"page":"533-539","source":"Crossref","is-referenced-by-count":11,"title":["Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"Alan N","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J","family":"Messing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daron G","family":"Street","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Charles H","family":"Pippitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl L","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.05.021_BIB1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJM197210262871705","article-title":"Treatment of ovarian carcinoma: possibilities for progress","volume":"287","author":"Bagley","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0959-8049(02)00161-2","article-title":"Ovarian cancer: progress and continuing controversies in management","volume":"38","author":"Moss","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.021_BIB4","series-title":"Cancer: Principles and Practice of Oncology","first-page":"1597","article-title":"Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma","author":"Ozols","year":"2001"},{"key":"10.1016\/j.ygyno.2004.05.021_BIB5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"5 Suppl 15","key":"10.1016\/j.ygyno.2004.05.021_BIB7","first-page":"S1544","article-title":"Carboplatin\/paclitaxel versus cisplatin\/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the arbeitsgemeinschaft gynakologische onkologie ovarian cancer study group","volume":"24","author":"du Bois","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB8","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB9","first-page":"356a","article-title":"Randomized phase III study of cisplatin (CIS)\/paclitaxel (PAC) versus carboplatin (CARBO)\/PAC in optimal stage III epithelial ovarian cancer (OC): a gynecologic oncology group trial (GOG 158) [abstract]","volume":"18","author":"Ozols","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2004.05.021_BIB10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1008323922057","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(98)04119-1","article-title":"ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"1 Suppl 5","key":"10.1016\/j.ygyno.2004.05.021_BIB12","first-page":"S519","article-title":"Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma","volume":"24","author":"ten Bokkel Huinink","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB13","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB16","first-page":"350a","article-title":"A phase I study of topotecan (T), cisplatin (C) and paclitaxel (P) in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study [abstract]","volume":"17","author":"Armstrong","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.1999.17.3.747","article-title":"Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer","volume":"17","author":"Herben","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/gyno.2001.6581","article-title":"Phase I study of alternating doublets of topotecan\/carboplatin and paclitaxel\/carboplatin in patients with newly diagnosed, advanced ovarian cancer","volume":"85","author":"Gordon","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB19","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/gyno.2001.6179","article-title":"Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer","volume":"81","author":"Bolis","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1008301222560","article-title":"Cisplatin\u2013topotecan\u2013paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study","volume":"10","author":"Frasci","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB22","first-page":"213a","article-title":"Phase II study of sequential topotecan HCI (T) in combination with carboplatin (C) followed by paclitaxel (P) via three-hour infusion in combination with carboplatin (C) in the treatment of newly diagnosed ovarian cancer (OvCa) patients (pts) with advanced disease [abstract]","volume":"21","author":"Gordon","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB23","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2000.18.24.4038","article-title":"Phase II feasibility study of sequential couplets of cisplatin\/topotecan followed by paclitaxel\/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"18","author":"Hoskins","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB24","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.021_BIB25","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.1996.14.12.3074","article-title":"Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence","volume":"14","author":"Rowinsky","year":"1996","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T05:26:25Z","timestamp":1549430785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804003191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0090825804003191"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}